A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome

Annals of Oncology

Volumn 23, Issue 6, 2012, Pages 1640-1645

  Vadhan raj, S ^a   Fayad, L E ^a   Fanale, M A ^a   Pro, B ^a,c   Rodriguez, A ^a   Hagemeister, F B ^a   Bueso ramos, C E ^a   Zhou, X ^a   Mclaughlin, P W ^a   Fowler, N ^a   Shah, J ^a   Orlowski, R Z ^a   Samaniego, F ^a   Wang, M ^a   Cortes, J E ^a   Younes, A ^a   Kwak, L W ^a   Sarlis, N J ^b,d   Romaguera, J E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SANOFI   (France)

^c Experimental Station   (United States)

^d FOX CHASE CANCER CENTER   (United States)

Author keywords

Hematologic malignancy; Hyperuricemia; Rasburicase; Tumor lysis syndrome

Indexed keywords

RASBURICASE; URIC ACID;

ADULT; AGED; ANAPHYLAXIS; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DYSPNEA; FEMALE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; GOUT; HEMOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; METHEMOGLOBINEMIA; NAUSEA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; VOMITING;

EID: 84861726903     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr490     Document Type: Article

References (32)

1. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993; 94: 133-139.
2. Hochberg J, Cairo MS. Tumor lysis syndrome: current perspective. Haematologica 2008; 93: 9-13.
3. Mughal TI, Ejaz AA, Foringer JR, Coifffier B. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. Cancer Treat Rev 2010; 36: 164-176.
4. Shimada M, Johnson RJ, May WS Jr et al. A novel role for uric acid in acute kidney injury associated with tumor lysis syndrome. Nephrol Dial Transplant 2009; 24: 2960-2964.
5. Coiffer B, Altman A, Pui C-H et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26: 2767-2778.
6. Tosi P, Barosi G, Lazzaro C et al. Consensus conference on the management of tumor lysis syndrome. Haematologica 2008; 93: 1877-1885.
7. Cairo MS, Bishop M. Tumor lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004; 127: 3-11.
8. Goldman SC, Holcenberg JS, Finklestein JZ et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia and high-risk for tumor lysis. Blood 2001; 97: 2998-3003.
9. Smalley RV, Guaspari A, Haase-Statz et al. Allopurirnol: intravenous use for prevention and treatment of hyperuricemia. J Clin Oncol 2000; 18: 1758-1763.
10. Cortes J, Moore JO, Maziarz RT et al. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone-results of a multicenter Phase III Study. J Clin Oncol 2010; 28: 4207-4213.
11. Elitek® (rasburicase) [Package Insert]. Bridgewater, NJ: Sanofi-Aventis 2008.
12. Liu CY, Sims-McCallum RP, Schaffer CA. A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. Leuk Res 2005; 29: 463-465.
13. McDonnell AM, Lenz KL, Frei-Lahr DA et al. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy 2006; 26: 806-812.
14. Reeves DJ, Bestul DJ. Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer. Pharmacotherapy 2008; 28: 685-690.
15. Campara M, Shord SS, Haaf CM. Single-dose rasburicase for tumor lysis syndrome in adults: weight-based approach. J Clin Pharm Ther 2009; 34: 207-213.
16. Trifillo S, Gordon L, Singhal S et al. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant 2006; 37: 997-1001.
17. Hummel M, Buchheidt D, Reiter S et al. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia-successful treatment and prevention of TLS with low-dose rasburicase. Eur J Haematol 2005; 75: 518-521.
18. Lee AC, Li CH, So KT, Chan R. Treatment of impending lumor lysis with single-dose rasburicase. Ann Pharmacother 2003; 37: 1614-1617.
19. Hummel M, Reiter S, Adam K et al. Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase. Eur J Haematol 2008; 80: 331-336.
20. Hutcherson DA, Gammon DC, Bhatt MS, Faneuf M. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy 2006; 26: 242-247.
21. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
22. Harris NL, Jaffe ES, Diebold J et al. Lymphoma classification-from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms. Ann Oncol 2000; 11 (Suppl 1): 3-10.
23. He J. SAS Programming to Calculate AUC in Pharmacokinetic Studies-Comparison of Four Methods in Concentration Data. SAS Institute 2008. http://www.lexjansen.com/pharmasug/2008/sp/sp06.pdf (10 November 2011, date last accessed).
24. Ejaz AA, Beaver TM, Shimada M et al. Uric Acid: a novel risk factor for acute kidney injury in high-risk cardiac surgery patients? Am J Nephrol 2009; 30: 425-429.
25. Cairo MS, Casciano R, Morris E et al. Uric acid (UA) level is a significant prognostic factor in the development of tumor lysis syndrome (TLS) and renal events (RE) in non-Hodgkin's lymphoma (NHL) in patients admitted for inpatient chemotherapy (IC). Ann Oncol 2002; 13: 174 (Abstr 624).
26. Goldman S, Lynch J, Harrison L et al. Preliminary results of the addition of rasburicase to the reduction cycle and rituximab to the induction and consolidation cycles of FAB Group C chemotherapy in children and adolescents with advanced stage (bone Marrow 6CNS) mature B-Cell non-Hodgkin lymphoma (B-NHL): a Children's Oncology Group report. Blood 2009; 114: 22 (Abstr 104).
27. Kizer N, Martinez E, Powell M. Report of two cases of rasburicase-induced methemoglobinemia. Leuk Lymphoma 2006; 47: 2648-2650.
28. Jeha S, Kantarjian H, Irwin D et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005; 19: 34-38.
29. Coiffier B, Mounier N, Bologna S et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003; 21: 4402-4406.
30. Browning LA, Kruse J. Hemolysis and methemoglobinemia secondary to rasburicase administration. Ann Pharmacother 2005; 39: 1932-1935.
31. Landis RC, Haskard DO. Pathogenesis of crystal-induced inflammation. Curr Rheumatol Rep 2001; 3: 36-41.
32. Neogi T. Gout. N Engl J Med 2011; 364: 443-452.